All In Biotech

Drug Trial Radar · NCT01277211

A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)

A Randomized, Open-Label, Controlled, Multi-Center Trial to Evaluate the Contraceptive Efficacy, Cycle Control, Safety and Acceptability of NuvaRing® (SCH 900702) in Chinese Women

Last checked: Nov 20, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 983 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

983

Actual

Start

Sep 19, 2011

Primary completion

Sep 18, 2013

Study completion Sep 18, 2013

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Jan 14, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a study to assess the effectiveness of NuvaRing® (SCH 900702) for the prevention of pregnancy in fertile Chinese women. The acceptability and safety of NuvaRing® will also be assessed and compared with that of Yasmin.

Conditions

  • Contraception

Interventions

  • ENG 120 µg + EE 15 µg intravaginal ringDrug

    13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.

  • DRSP 3 mg + EE 30 µgDrug

    13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pearl Index, by Treatment GroupTime frame: Up to 1 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.